Cholangiocarcinoma Market Estimated to Witness High Growth |...

Cholangiocarcinoma Market Estimated to Witness High Growth

Posted 2024-08-20 12:53:06

451

The Cholangiocarcinoma market is characterised by continuous product approvals and launch of novel targeted therapies. Cholangiocarcinoma refers to a rare type of cancer that forms in the bile ducts. Symptoms include jaundice, abdominal pain and weight loss. Currently, surgery offers the best chance of cure if the cancer is diagnosed at an early stage, prior to spreading. However, recurrence is common even after surgical removal of the tumour. Numerous pharmaceutical companies are investing in research and development to discover novel targeted therapies that can improve survival and quality of life for patients.

The Global Cholangiocarcinoma Market is estimated to be valued at US$ 618.59 Mn in 2024 and is expected to exhibit a CAGR of 20.% over the forecast period 2024 To 2031.

Advancements in targeted therapies have emerged as a Cholangiocarcinoma Market Demand Companies are focusing on development of drugs that target specific mutations driving cancer growth. Several pipeline candidates are under evaluation including inhibitors of fibroblast growth factor receptor and epidermal growth factor receptor pathways.

Key Takeaways
Key players operating in the Cholangiocarcinoma market include BridgeBio Inc., Sanofi, Eisai Co., Ltd., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Fresenius SE and Co. KGaA, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Incyte, TRISALUS LIFE SCIENCES, INC., GENFIT, Johnson and Johnson Private Limited, Bliss Biopharmaceutical, Novartis AG, LES LABORATOIRES SERVIER, F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris.Inc), AstraZeneca, Compass Therapeutics, Inc, Otsuka Holdings Co., Ltd., and Senhwa Biosciences, Inc.

Cholangiocarcinoma Market Size And Trends lie in immunotherapies that help mobilize the body's immune system to combat cancer. Companies are investigating vaccines, immune checkpoint inhibitors and other immunotherapy drugs for cholangiocarcinoma. Another breakthrough area is use of liquid biopsies for non-invasive detection of disease, monitoring treatment response and detecting relapse.

Get More Insights On, Cholangiocarcinoma Market